Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LatviaBack to Latvia

Clinical trials in Riga – page 4

203 clinical trials in Riga, Latvia across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Riga at a glance
203
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

203 trials in Riga

Open in trial search

Epileptic encephalopathy

Recruiting

Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Glioblastoma

Recruiting

Study on Adding Zoledronic Acid to Standard Treatment for Patients with Glioblastoma

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid Monohydrate
  • Sponsor:Pauls Stradins Clinical University Hospital

Immune thrombocytopenia

Recruiting

Study on the Effectiveness and Safety of Efgartigimod IV for Adults with Primary Immune Thrombocytopenia

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neurogenic bladder

Recruiting

Study on the Safety and Effectiveness of Vibegron for Children Aged 2 to 17 with Neurogenic Bladder Overactivity Using Clean Intermittent Catheterization

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Vibegron
  • Sponsor:Sumitomo Pharma America Inc.

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure chronic+1

Recruiting

Study on Meldonium and Physical Activity for Patients with Heart Failure with Preserved Ejection Fraction

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Meldonium
  • Sponsor:Pauls Stradins Clinical University Hospital

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting
Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Acute myeloid leukaemia

Recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Riga

What the registry says about research in the country

01 Immunology & Vaccines

Research focusing on vaccine development and immune responses, including studies of combined vaccines for childhood diseases and immune system modulation in various conditions.

  • Measles-Mumps-Rubella-Varicella vaccine studies
  • Primary Immune Thrombocytopenia treatments
  • Novel immunotherapy approaches
02 Metabolic & Endocrine Disorders

Investigations into metabolic conditions and hormone-related disorders, with emphasis on treatment innovations and management strategies.

  • Glucagon response studies
  • Hypertriglyceridemia management
  • Post-menopausal osteoporosis treatment
03 Inflammatory Conditions

Clinical research targeting various inflammatory diseases, including dermatological and rheumatological conditions.

  • Psoriatic arthritis treatments
  • Plaque psoriasis therapies
  • Ulcerative colitis interventions
04 Oncology & Neurology

Studies focusing on innovative treatments for cancer and neurological disorders, including targeted therapies and combination approaches.

  • Non-small cell lung cancer treatments
  • Glioblastoma therapy
  • Dravet Syndrome management
05 Respiratory & Cardiovascular

Research into pulmonary conditions and heart-related disorders, exploring new therapeutic approaches.

  • Pulmonary arterial hypertension
  • Asthma treatment innovations
  • Heart failure interventions
Back to LatviaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.